

[Rasburicase](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.5. Supportive medicines](#)

ATC codes: [V03AF07](#)

EMLc

Indication

Tumour lysis syndrome ICD11 code: [5C70](#)

INN

Rasburicase

Medicine type

Biological agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution ; 7.5 mg in vial powder and 5 mL solvent for solution

EML status history

First added in 2021 ([TRS 1035](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer supportive care Cancer

Wikipedia

[Rasburicase](#)

DrugBank

[Rasburicase](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to modify the formulation descriptions to better describe the available dosage forms.